IL1B and alcoholic hepatitis: Canakinumab, a monoclonal antibody selectively inhibiting IL‐1β, has been tested in alcoholic hepatitis in a phase 2 RCT, where it led to histological improvements on liver biopsy but this did not translate into improved survival or Model for End‐Stage Liver Disease (MELD) score (NCT03775109).